Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Ruthy Tal-Jasper"'
Autor:
Naama Epstein-Rigbi, Sharon Ziv, Marina Bulanenkova, Ruth Bouganim, Ruthy Tal-Jasper, Dror Marchaim
Publikováno v:
Antimicrobial Stewardship & Healthcare Epidemiology, Vol 4 (2024)
Abstract Background: A beta-lactam antibiotics (BLA) allergy label is common, resulting in disadvantageous outcomes due to the usage of second-line antimicrobial agents. Noncontrolled case-series analyses report low rates of hypersensitivity reactio
Externí odkaz:
https://doaj.org/article/f2949489e26b4b988252a6eaa1d56a60
Autor:
Ronit Zaidenstein, Asaf Miller, Ruthy Tal-Jasper, Hadas Ofer-Friedman, Menachem Sklarz, David E. Katz, Tsillia Lazarovitch, Paul R. Lephart, Bethlehem Mengesha, Oran Tzuman, Mor Dadon, Chen Daniel, Jacob Moran-Gilad, Dror Marchaim
Publikováno v:
Microorganisms, Vol 6, Iss 1, p 9 (2018)
It is unknown as to whether other beta-lactams can be used for bloodstream infections (BSI) resulting from Pseudomonas aeruginosa (PA) which are non-susceptible to one or more carbapenem. We conducted a retrospective cohort study at the Assaf Harofeh
Externí odkaz:
https://doaj.org/article/bd7a9522d9dd413f8f1e76a540afb0be
Autor:
Dror Marchaim, David E. Katz, Ruthy Tal-Jasper, Nadav Amrami, Ronit Zaidenstein, Mor Dadon, Keith S. Kaye, Tsilia Lazarovitch, Dori Avivi, Dor Ravid
Publikováno v:
Antimicrobial Agents and Chemotherapy. 60:3127-3131
Carbapenems are considered the treatment of choice for Acinetobacter baumannii infections. Many facilities implement preventive measures toward only carbapenem-resistant A. baumannii (CRAB). However, the independent role of the carbapenem resistance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e0f900df9694e2d1fa4c7c4f4763f2f
https://doi.org/10.1128/aac.02656-15
https://doi.org/10.1128/aac.02656-15
Autor:
Dror Marchaim, Mor Dadon, David E. Katz, Ruthy Tal-Jasper, Tzach Aviv, Ronit Zaidenstein, Tsillia Lazarovitch, Chen Daniel, Keith S Kaye
Publikováno v:
Infection control and hospital epidemiology. 39(10)
A case–case-control investigation (N = 255 patients) explored the epidemiology of carbapenem-resistant Pseudomonas aeruginosa (CRPA). Recent exposure to carbapenems and a rapidly fatal condition should prompt practitioners to shorten delays in init
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6de3121f962e9ca2dde56bbff7a9f57e
https://pubmed.ncbi.nlm.nih.gov/30103833
https://pubmed.ncbi.nlm.nih.gov/30103833
Autor:
Dror Marchaim, Menachem Sklarz, Chen Daniel, Asaf Miller, Oran Tzuman, Paul R. Lephart, Hadas Ofer-Friedman, Bethlehem Mengesha, Ronit Zaidenstein, Tsillia Lazarovitch, Mor Dadon, Jacob Moran-Gilad, David E. Katz, Ruthy Tal-Jasper
Publikováno v:
Microorganisms; Volume 6; Issue 1; Pages: 9
Microorganisms
Microorganisms, Vol 6, Iss 1, p 9 (2018)
Microorganisms
Microorganisms, Vol 6, Iss 1, p 9 (2018)
It is unknown as to whether other beta-lactams can be used for bloodstream infections (BSI) resulting from Pseudomonas aeruginosa (PA) which are non-susceptible to one or more carbapenem. We conducted a retrospective cohort study at the Assaf Harofeh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01d1b03e406337fc0c8b6dcb1bf8f530
Autor:
Keren Amity, Ruthy Tal-Jasper, Keith S. Kaye, Tsilia Lazarovitch, Robert A. Bonomo, Dror Marchaim, Christopher Bogan, Ronit Zaidenstein, Tal Azouri, Tamir Kaplansky, Kayoko Hayakawa, Benjamin Ackerman, Joseph R. Coyle, Hadas Ofer-Friedman, Moran Maskit, Federico Perez, Paul R. Lephart
Publikováno v:
Infection control and hospital epidemiology. 36(11)
BACKGROUNDThe pandemic of carbapenem-resistant Enterobacteriaceae (CRE) was primarily due to clonal spread ofblaKPCproducingKlebsiella pneumoniae. Thus, thoroughly studied CRE cohorts have consisted mostly ofK. pneumoniae.OBJECTIVETo conduct an exten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f156f449b2e37b00180b59288f0462f
https://pubmed.ncbi.nlm.nih.gov/26399907
https://pubmed.ncbi.nlm.nih.gov/26399907
Publikováno v:
Future microbiology. 10(5)
ABSTRACT Antimicrobial resistance is a growing worldwide iatrogenic complication of modern medical care. Extended-spectrum β-lactamases have emerged as one of the most successful resistance mechanisms, limiting our therapeutic options to treat vario
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8796e5955d19f28b042fa8965ea92a83
https://pubmed.ncbi.nlm.nih.gov/26000652
https://pubmed.ncbi.nlm.nih.gov/26000652
Autor:
Amit Tirosh, Pradeep Bathina, Keith S. Kaye, Dror Marchaim, Tamir Kaplansky, Ronit Zaidenstein, Tal Azouri, Hadas Ofer-Friedman, Coral Shefler, Ruthy Tal-Jasper, Sarit Sharma, Moran Maskit, Deepthi Kandipalli, Tsilia Lazarovitch, Shruti Sharma
Publikováno v:
Infection control and hospital epidemiology. 36(8)
A recent, frequently quoted study has suggested that for bloodstream infections (BSIs) due to extended-spectrum β-lactamase–producing Enterobacteriaceae (ESBL) Escherichia coli, treatment with β-lactam/β-lactamase inhibitors (BLBLIs) might be eq
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3d79e3f467e57fce8f01b8fe08a89d4
https://pubmed.ncbi.nlm.nih.gov/25990361
https://pubmed.ncbi.nlm.nih.gov/25990361
Autor:
Tamir Kaplansky, Coral Shefler, Emily T. Martin, Tsilia Lazarovitch, Ruthy Tal-Jasper, Ronit Zaidenstein, Dror Marchaim, Kayoko Hayakawa, Violet Leibman, Leonti Grin, Keith S. Kaye, Moran Maskit, Tal Azouri
Publikováno v:
Annals of Clinical Microbiology and Antimicrobials
Background Epidemiological characteristics of patients with bloodstream infections (BSI) due to extended-spectrum β-lactamase producing (ESBL) and carbapenem-resistant (CRE) strains are often similar. Mortality rates for CRE BSI are 70 %, and mean t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50b8538d41474d42e64630987f922ac5